What Effect Does Ethnicity Have on the Response to Ranibizumab in the Treatment of Wet Age-Related Macular Degeneration?

Abstract

Aims: To compare, in a single urban population, the visual outcomes of ranibizumab monotherapy in “White” (W) and “Non-White” (NW) patients with wet age-related macular degeneration (AMD). Procedures: Prospective data was collected from 434 eyes of 217 patients with wet AMD patients receiving intravitreal ranibizumab. Baseline and monthly LogMAR visual acuities were obtained. All patients received treatment under a “treat and extend policy” consisting of three monthly injections of ranibizumab, followed by individualised sequentially lengthening follow-up intervals when stable. Results: At 24 months, the percentage of eyes that maintained or improved vision was 91% in W patients and 83% in NW patients. Correspondingly, at 24 months, the percentage of visual loss was 9% for W patients and 17% of NW patients. We found that whilst W patients required fewer overall injections (14.1) they gained an average 4 LogMAR letters of visual acuity. However, NW patients required more injections (14.6) to gain 0.5 LogMAR letters of visual acuity over the same 24 months of treatment. Conclusions: Individualised ranibizumab monotherapy is more effective in preserving vision for W compared to NW patients with wet AMD.